

18 June 2024

**BSF Enterprise PLC**  
("BSF" or the "Company")

**NOTIFICATION OF TRANSACTIONS OF DIRECTORS**

BSF (LSE: BSFA), (OTCQB: BSFAF), has received notification from its CFO, Graham Duncan, being a person discharging managerial responsibilities, of the purchase of shares as set out in the notification of dealing form here:

[http://bsfenterprise.com/wp-content/uploads/2024/06/PDMR\\_Notification\\_00380329.pdf](http://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification_00380329.pdf)

For further enquiries, please visit [www.bsfenterprise.com](http://www.bsfenterprise.com) or contact:

**BSF Enterprise PLC**  
Geoff Baker - Executive Director  
Che Cannon - CEO & Director

Via SEC Newgate below

**Shard Capital (Broker)**  
Damon Heath  
Isabella Pierre

0207 186 9000  
0207 186 9927

**SEC Newgate (Financial Communications)**  
Bob Huxford  
Elisabeth Cowell  
George Esmond

020 3757 6882  
[BSF@secnewgate.co.uk](mailto:BSF@secnewgate.co.uk)

*ISIN of the Ordinary Shares is GB00BHNBDQ51  
SEDOL Code is BHNBDQ5.*

**Notes to Editors**

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions to deliver sustainable materials and products across a variety of sectors. BSF Enterprise's core technology platform in industrial tissue engineering allows the manufacture at scale of lab-grown alternatives to animal and human tissues, helping deliver sustainable products and materials of the future. The Company's technologies have multiple applications across consumer and medical markets including lab-grown leather, cultivated meat, human corneas and in vitro animal models.

BSF owns 100% of pioneering UK-based tissue engineering companies 3D Bio-Tissues (3DBT), that successfully produced the UK's first high-quality cultivated meat and lab-grown skin from its laboratory and Kerato, a developer of lab-grown corneal replacement tissue for medical and research uses. In addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively supporting commercialisation of our technology in China and Asia.

BSF aims to deliver growth to shareholders through the continued commercialisation and expansion of the Groups IP, which

has multiple applications, as well as through M&A. BSF aims to build a comprehensive portfolio in tissue engineering and related applications and license out IP to various stakeholders in the supply chain to enable manufacture at scale and achieve widespread market penetration.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFIFEERFITLIS